The invention relates to an oral pharmaceutical composition of albendazole comprising 30-50% w/w of albendazole, 1-3% w/w of binder and 5-15% w/w of disintegrant, wherein disintegrant is selected from sodium starch glycolate, crosscarmellose sodium or both. The composition and their derived oral pharmaceutical compo...

The invention relates to oral pharmaceutical composition clomiphene citrate comprising 15-30% w/w of clomiphene citrate, 2-5% w/w of binder and 0.5-5% w/w of disintegrant, wherein disintegrant is selected from polyvinyl-n-pyrrolidone and at least 90% particles of active pharmaceutical ingredient is having a size of...